

**ELISpot and FluoroSpot Assay Market by Product (Assay kit (Technique, Utility, Analyte (T Cell and B Cell assay)), Analyzer), Application (Transplants, Infectious Diseases, Vaccine Development, Cancer Research), End User - Global Forecast to 2028**

Market Report | 2023-11-20 | 234 pages | MarketsandMarkets

**AVAILABLE LICENSES:**

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

**Report description:**

The global ELISpot and FluoroSpot Assays Market is expected to reach USD 421 million by 2028 from USD 292 million in 2023, at a CAGR of 7.6% during the forecast period. Market is driven by factors such as Increasing use of ELISpot and FluoroSpot assays in oncology, growth in biotechnology and biopharmaceutical industries. On the other hand, availability of alternative detection technologies is expected to limit market growth to a certain extent in the coming years.

"The Assay kits accounted for the largest market share in the ELISpot and FluoroSpot Assays product' smarket, during the forecast period"

The ELISpot and FluoroSpot Assay Products market is segmented into Assay kits, Analyzers, and Ancillary Products. In 2022, kits accounted for a sizable market share because they offer advantages in terms of high specificity and sensitivity and better detection limits as compared to other assays such as ELISA as well as their wide applications in the field of research and diagnostics.

"Diagnostic application segment accounted for the largest market share"

Based on type of application, the ELISpot and FluoroSpot Assays market is segmented into Diagnostic and Research Application. The Diagnostic application segment accounted for the largest market share in 2022., while research application is expected to grow at the fastest rate in the years ahead, from 2023 to 2028 considering their practice in several research applications, such as vaccine development, clinical trials, and cancer research.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

"APAC region accounted for the highest CAGR"

The global ELISpot and FluoroSpot Assays market is divided into four regions: North America, Asia-Pacific, Europe, and Rest of the World. According to the regional analysis, the Asia-Pacific region is likely to retain a significant market share in 2022 and the future. The Asia-Pacific market is being propelled by an increase in non-communicable (NCD), research funding on vaccines and changing disease profiles. North America, on the other hand, will experience significant growth in the coming years due to the presence of key players, the availability of technologically advanced ELISpot and FluoroSpot assay kits and analyzers.

"Europe is estimated to register the third highest CAGR during the forecast period."

In this report, the ELISpot and FluoroSpot Assays market is segmented into four major regional segments: North America, Europe, Asia Pacific, Rest of the world. The market in Europe is projected to register the third highest growth rate during the forecast period. The growth in this market is due to Europe has a strong tradition of research and academic excellence, the rising incidence of chronic diseases, including autoimmune disorders and infectious diseases, government funding for research and healthcare in many European countries supports the development and adoption of advanced diagnostic technologies.

The primary interviews conducted for this report can be categorized as follows:

- By Company Type: Tier 1 - 32%, Tier 2 - 44%, and Tier 3 - 24%
- By Designation: C-level - 30%, D-level - 34%, and Others - 36%
- By Region: North America - 40%, Europe - 28%, Asia Pacific - 20%, and the Rest of the World - 12%

Lits of Companies Profiled in the Report:

- Oxford Immunotec USA, Inc. (Subsidiary of Revvity Inc.) (UK)
- Becton, Dickinson and Company (BD) (US)
- Cellular Technology Limited (CTL) (US)
- Mabtech (Sweden)
- Abcam plc. (UK)
- Bio-Techne (US)
- Merck KGaA (Germany)
- Autoimmun Diagnostika GmbH (Germany)
- U-CyTech (Netherland)
- Mikrogen Diagnostik (Germany)
- Medix Biochemica (Finland)
- Abnova Corporation (Taiwan)
- Anogen-Yes Biotech Laboratories Ltd. (Canada)
- Biorbyt Ltd (UK)
- BIOSYS Scientific Devices GmbH (Germany)
- Jackson ImmunoResearch Inc. (US)
- iST Scientific (UK)
- SERVA Electrophoresis GmbH (Germany)
- ACROBiosystems (US)
- NATIONAL ANALYTICAL CORPORATION (India)
- STEMCELL Technologies. (Canada)
- ZenBio, Inc (US)
- BOC Sciences (US)
- Tokyo Chemical Industry Co., Ltd. (TCI) (Japan)
- MP Biomedicals (California)

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

## Research Coverage:

This report studies the ELISpot and FluoroSpot Assays market based on product, applications, End user, and region. The report also analyses factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total ELISpot and FluoroSpot Assays market. The report forecasts the revenue of the market segments with respect to four major regions.

## Reasons to Buy the Report:

The report provides insights on the following pointers:

**Market Drivers:** Comprehensive information about driving factors of the markets. The report analyses the markets drivers across key geographic regions.

**Market Penetration:** Comprehensive information on ELISpot and FluoroSpot assay products offered by the top 25 players in the market. The report analyses the ELISpot and FluoroSpot Assays market by product, application, end user and region.

**Market Development:** Comprehensive information about lucrative emerging markets. The report analyses the markets for various securement devices across key geographic regions.

**Market Diversification:** Exhaustive information about untapped geographies, recent developments, and investments in the ELISpot and FluoroSpot Assays market

**Competitive Assessment:** In-depth assessment of market shares and strategies of the leading players in the ELISpot and FluoroSpot Assays market

**Market Position:** It will upkeep stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies.

## Table of Contents:

1	INTRODUCTION	32
1.1	STUDY OBJECTIVES	32
1.2	MARKET DEFINITION	32
1.2.1	INCLUSIONS AND EXCLUSIONS OF STUDY	33
1.3	MARKET SCOPE	34
1.3.1	MARKET SEGMENTATION	34
1.3.2	REGIONAL SEGMENTATION	34
1.3.3	YEARS CONSIDERED	35
1.4	CURRENCY	35
1.5	LIMITATIONS	35
1.6	MARKET STAKEHOLDERS	36
1.7	SUMMARY OF CHANGES	36
1.8	RECESSION IMPACT	37
2	RESEARCH METHODOLOGY	38
2.1	RESEARCH DATA	38
FIGURE 1	RESEARCH DESIGN	38
2.1.1	SECONDARY DATA	39
2.1.1.1	Secondary sources	39
2.1.2	PRIMARY DATA	40
FIGURE 2	PRIMARY SOURCES	40
2.1.2.1	Key data from primary sources	41

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

2.1.2.2	Key industry insights	42
2.1.2.3	Breakdown of primary interviews	43
FIGURE 3	BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS	43
FIGURE 4	BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION	43
2.2	MARKET SIZE ESTIMATION	44
FIGURE 5	REVENUE SHARE ANALYSIS ILLUSTRATION: OXFORD IMMUNOTEC USA, INC. (SUBSIDIARY OF REVVITY, INC.) (UK)	44
FIGURE 6	MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH	45
2.2.1	GROWTH FORECAST	45
FIGURE 7	CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS	46
FIGURE 8	TOP-DOWN APPROACH	46
2.3	MARKET BREAKDOWN AND DATA TRIANGULATION	48
FIGURE 9	DATA TRIANGULATION METHODOLOGY	48
2.4	MARKET SHARE ANALYSIS	49
2.5	STUDY ASSUMPTIONS	49
2.6	RISK ASSESSMENT	49
TABLE 1	RISK ASSESSMENT	49
2.7	RECESSION IMPACT ANALYSIS	50
3	EXECUTIVE SUMMARY	51
FIGURE 10	ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)	51
FIGURE 11	ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)	52
FIGURE 12	ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)	52
FIGURE 13	ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY REGION, 2023 VS. 2028 (USD MILLION)	53
4	PREMIUM INSIGHTS	54
4.1	ELISPOT AND FLUOROSPOT ASSAYS MARKET OVERVIEW	54
FIGURE 14	RIISING INCIDENCE OF CHRONIC AND INFECTIOUS DISEASES TO DRIVE MARKET	54
4.2	ELISPOT AND FLUOROSPOT ASSAY KITS MARKET, BY TECHNIQUE, 2023-2028	54
FIGURE 15	ELISPOT ASSAY KITS TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD	54
4.3	NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT AND COUNTRY (2022)	55
FIGURE 16	ASSAY KITS ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN ELISPOT AND FLUOROSPOT ASSAYS MARKET IN 2022	55
4.4	ELISPOT AND FLUOROSPOT ASSAYS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES	56
FIGURE 17	ASIA PACIFIC COUNTRIES TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD	56
5	MARKET OVERVIEW	57
5.1	INTRODUCTION	57
5.2	MARKET DYNAMICS	57
FIGURE 18	ELISPOT AND FLUOROSPOT ASSAYS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES	57
5.2.1	DRIVERS	58
5.2.1.1	Increasing incidence of chronic and infectious diseases and growing awareness about early disease diagnosis	58
FIGURE 19	INCIDENCE OF DIABETES, BY REGION, 2019 VS. 2030 VS. 2045 (MILLION)	58
TABLE 2	GLOBAL INCIDENCE OF INFECTIOUS DISEASES	59
5.2.1.2	Increasing vaccine development to address challenges of antimicrobial resistance	59
5.2.1.3	Increasing use of ELISpot and FluoroSpot assays in oncology	61
TABLE 3	INCIDENCE OF CANCER IN MEN, 2020	61
TABLE 4	INCIDENCE OF CANCER IN WOMEN, 2020	61
5.2.1.4	ELISpot assays as diagnostic tool in drug hypersensitivity reaction	62
TABLE 5	EXAMPLES OF ELISPOT ASSAYS IN DRUG HYPERSENSITIVITY REACTIONS	63
5.2.1.5	Growth in biotechnology and biopharmaceutical industries	63

5.2.2	RESTRAINTS	64
5.2.2.1	Stringent requirements for approval of ELISpot and FluoroSpot assay instruments and consumables	64
5.2.2.2	High cost of assay kits and analyzers	65
5.2.3	OPPORTUNITIES	65
5.2.3.1	Use of FluoroSpot assays for multiple-analyte detection in single well	65
5.2.3.2	Emerging economies	66
FIGURE 20	HEALTHCARE EXPENDITURE PER CAPITA IN BRIC COUNTRIES, 2012-2020	67
5.2.4	CHALLENGES	67
5.2.4.1	Availability of alternative detection technologies	67
5.2.4.2	Dearth of skilled professionals	67
5.3	VALUE CHAIN ANALYSIS	68
FIGURE 21	VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES	68
5.4	SUPPLY CHAIN ANALYSIS	69
FIGURE 22	DIRECT DISTRIBUTION-PREFERRED STRATEGY FOR PROMINENT COMPANIES	69
5.5	TECHNOLOGY ANALYSIS	70
5.6	PORTER'S FIVE FORCES ANALYSIS	70
5.6.1	THREAT OF NEW ENTRANTS	71
5.6.2	INTENSITY OF COMPETITIVE RIVALRY	71
5.6.3	BARGAINING POWER OF BUYERS	71
5.6.4	BARGAINING POWER OF SUPPLIERS	71
5.6.5	THREAT OF SUBSTITUTES	71
5.7	KEY STAKEHOLDERS AND BUYING CRITERIA	72
5.7.1	KEY STAKEHOLDERS IN BUYING PROCESS	72
FIGURE 23	INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS	72
TABLE 6	INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS (%)	72
5.7.2	BUYING CRITERIA	72
FIGURE 24	KEY BUYING CRITERIA FOR END USERS	72
TABLE 7	KEY BUYING CRITERIA FOR END USERS	73
5.8	REGULATORY LANDSCAPE	73
TABLE 8	REGULATORY AUTHORITIES GOVERNING ELISPOT AND FLUOROSPOT ASSAYS MARKET	73
5.8.1	US	74
TABLE 9	US: CLASSIFICATION OF ELISPOT AND FLUOROSPOT ASSAY PRODUCTS	74
FIGURE 25	US: REGULATORY PROCESS FOR IVD DEVICES	75
5.8.2	CANADA	76
FIGURE 26	CANADA: REGULATORY PROCESS FOR IVD DEVICES	76
5.8.3	EUROPE	76
TABLE 10	EUROPE: CLASSIFICATION OF IVD DEVICES	77
5.8.4	JAPAN	78
FIGURE 27	JAPAN: REGULATORY PROCESS FOR IVD DEVICES	78
TABLE 11	JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS	78
5.8.5	CHINA	79
TABLE 12	CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS	79
5.8.6	INDIA	79
FIGURE 28	INDIA: REGULATORY PROCESS FOR IVD DEVICES	80
5.8.7	RUSSIA	80
TABLE 13	RUSSIA: CLASSIFICATION OF IVD DEVICES	80
5.8.8	SAUDI ARABIA	80

TABLE 14	SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS	81
5.8.9	MEXICO	81
FIGURE 29	MEXICO: REGULATORY PROCESS FOR IVD DEVICES	81
TABLE 15	MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS	82
5.8.10	BRAZIL	83
FIGURE 30	BRAZIL: REGULATORY PROCESS FOR IVD DEVICES	83
5.8.11	SOUTH KOREA	83
TABLE 16	SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS	83
5.8.12	MIDDLE EAST	84
5.8.13	AFRICA	84
5.9	KEY CONFERENCES AND EVENTS	84
TABLE 17	LIST OF CONFERENCES AND EVENTS, 2023-2025	84
5.10	PATENT ANALYSIS	85
FIGURE 31	PATENT ANALYSIS FOR ELISPOT AND FLUOROSPOT ASSAYS	85
5.11	PRICING ANALYSIS	86
TABLE 18	ELISPOT AND FLUOROSPOT ASSAYS MARKET: PRICE RANGE FOR ELISPOT AND FLUOROSPOT ASSAY PRODUCTS	86
TABLE 19	AVERAGE SELLING PRICE OF PRODUCTS OFFERED BY KEY PLAYERS (2022)	86
5.12	TRADE ANALYSIS	86
5.12.1	TRADE ANALYSIS FOR ELISPOT AND FLUOROSPOT ASSAYS	86
TABLE 20	IMPORT DATA FOR HS CODE 382200, BY COUNTRY, 2017-2022 (USD MILLION)	87
TABLE 21	EXPORT DATA FOR HS CODE 382200, BY COUNTRY, 2017-2022 (USD MILLION)	87
5.13	ECOSYSTEM ANALYSIS	88
5.13.1	ROLE IN ECOSYSTEM	88
FIGURE 32	KEY PLAYERS OPERATING IN ELISPOT AND FLUOROSPOT ASSAYS MARKET	89
5.14	TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS	89
6	ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT	90
6.1	INTRODUCTION	91
TABLE 22	ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020-2028 (USD MILLION)	91
6.2	ASSAY KITS	91
TABLE 23	ELISPOT AND FLUOROSPOT ASSAY KITS MARKET, BY REGION, 2020-2028 (USD MILLION)	92
TABLE 24	NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAY KITS MARKET, BY COUNTRY, 2020-2028 (USD MILLION)	92
TABLE 25	EUROPE: ELISPOT AND FLUOROSPOT ASSAY KITS MARKET, BY COUNTRY, 2020-2028 (USD MILLION)	92
TABLE 26	ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAY KITS MARKET, BY COUNTRY, 2020-2028 (USD MILLION)	93
6.2.1	ASSAY KITS MARKET, BY TECHNIQUE	93
TABLE 27	ELISPOT AND FLUOROSPOT ASSAY KITS MARKET, BY TECHNIQUE, 2020-2028 (USD MILLION)	93
6.2.1.1	ELISpot assay kits	93
6.2.1.1.1	Need for highly sensitive immune monitoring requirements in clinical trials to drive market	93
TABLE 28	ELISPOT ASSAY KITS MARKET, BY REGION, 2020-2028 (USD MILLION)	94
TABLE 29	NORTH AMERICA: ELISPOT ASSAY KITS MARKET, BY COUNTRY, 2020-2028 (USD MILLION)	94
TABLE 30	EUROPE: ELISPOT ASSAY KITS MARKET, BY COUNTRY, 2020-2028 (USD MILLION)	95
TABLE 31	ASIA PACIFIC: ELISPOT ASSAY KITS MARKET, BY COUNTRY, 2020-2028 (USD MILLION)	95
6.2.1.2	FluoroSpot assay kits	95
6.2.1.2.1	Increasing demand for multiple analyte detection and technological advancements to support market growth	95
TABLE 32	FLUOROSPOT ASSAY KITS MARKET, BY REGION, 2020-2028 (USD MILLION)	96
TABLE 33	NORTH AMERICA: FLUOROSPOT ASSAY KITS MARKET, BY COUNTRY, 2020-2028 (USD MILLION)	96
TABLE 34	EUROPE: FLUOROSPOT ASSAY KITS MARKET, BY COUNTRY, 2020-2028 (USD MILLION)	97
TABLE 35	ASIA PACIFIC: FLUOROSPOT ASSAY KITS MARKET, BY COUNTRY, 2020-2028 (USD MILLION)	97

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

## 6.2.2 ASSAY KITS MARKET, BY UTILITY 97

TABLE 36 ELISPOT AND FLUOROSPOT ASSAY KITS MARKET, BY UTILITY, 2020-2028 (USD MILLION) 97

### 6.2.2.1 Diagnostic kits 98

#### 6.2.2.1.1 Need for early diagnosis of infections to drive market 98

TABLE 37 CANCER CASES, BY TYPE, 2020 98

TABLE 38 DIAGNOSTIC KITS MARKET, BY REGION, 2020-2028 (USD MILLION) 98

TABLE 39 NORTH AMERICA: DIAGNOSTIC KITS MARKET, BY COUNTRY, 2020-2028 (USD MILLION) 99

TABLE 40 EUROPE: DIAGNOSTIC KITS MARKET, BY COUNTRY, 2020-2028 (USD MILLION) 99

TABLE 41 ASIA PACIFIC: DIAGNOSTIC KITS MARKET, BY COUNTRY, 2020-2028 (USD MILLION) 99

### 6.2.2.2 Research kits 100

#### 6.2.2.2.1 Increasing investments in vaccine research, clinical trials, and cancer research to drive market 100

TABLE 42 RESEARCH KITS MARKET, BY REGION, 2020-2028 (USD MILLION) 100

TABLE 43 NORTH AMERICA: RESEARCH KITS MARKET, BY COUNTRY, 2020-2028 (USD MILLION) 100

TABLE 44 EUROPE: RESEARCH KITS MARKET, BY COUNTRY, 2020-2028 (USD MILLION) 101

TABLE 45 ASIA PACIFIC: RESEARCH KITS MARKET, BY COUNTRY, 2020-2028 (USD MILLION) 101

## 6.2.3 ASSAY KITS MARKET, BY ANALYTE 101

TABLE 46 ELISPOT AND FLUOROSPOT ASSAY KITS MARKET, BY ANALYTE, 2020-2028 (USD MILLION) 101

### 6.2.3.1 T-cell-based kits 102

#### 6.2.3.1.1 Low concentrations of infection-released analytes necessitate use of T-cell-based kits 102

TABLE 47 T-CELL-BASED KITS MARKET, BY REGION, 2020-2028 (USD MILLION) 102

TABLE 48 NORTH AMERICA: T-CELL-BASED KITS MARKET, BY COUNTRY, 2020-2028 (USD MILLION) 102

TABLE 49 EUROPE: T-CELL-BASED KITS MARKET, BY COUNTRY, 2020-2028 (USD MILLION) 103

TABLE 50 ASIA PACIFIC: T-CELL-BASED KITS MARKET, BY COUNTRY, 2020-2028 (USD MILLION) 103

### 6.2.3.2 B-cell-based kits 103

#### 6.2.3.2.1 Detection of B-cell-based antibodies useful to study cell response post-infection/vaccination 103

TABLE 51 B-CELL-BASED KITS MARKET, BY REGION, 2020-2028 (USD MILLION) 104

TABLE 52 NORTH AMERICA: B-CELL-BASED KITS MARKET, BY COUNTRY, 2020-2028 (USD MILLION) 104

TABLE 53 EUROPE: B-CELL-BASED KITS MARKET, BY COUNTRY, 2020-2028 (USD MILLION) 104

TABLE 54 ASIA PACIFIC: B-CELL-BASED KITS MARKET, BY COUNTRY, 2020-2028 (USD MILLION) 105

### 6.2.3.3 Other analyte kits 105

TABLE 55 OTHER ANALYTE KITS MARKET, BY REGION, 2020-2028 (USD MILLION) 105

TABLE 56 NORTH AMERICA: OTHER ANALYTE KITS MARKET, BY COUNTRY, 2020-2028 (USD MILLION) 106

TABLE 57 EUROPE: OTHER ANALYTE KITS MARKET, BY COUNTRY, 2020-2028 (USD MILLION) 106

TABLE 58 ASIA PACIFIC: OTHER ANALYTE KITS MARKET, BY COUNTRY, 2020-2028 (USD MILLION) 106

## 6.3 ANALYZERS 107

### 6.3.1 ADOPTION OF ASSAY KITS TO DRIVE USE OF ANALYZERS 107

TABLE 59 ELISPOT AND FLUOROSPOT ANALYZERS MARKET, BY REGION, 2020-2028 (USD MILLION) 107

TABLE 60 NORTH AMERICA: ELISPOT AND FLUOROSPOT ANALYZERS MARKET, BY COUNTRY, 2020-2028 (USD MILLION) 107

TABLE 61 EUROPE: ELISPOT AND FLUOROSPOT ANALYZERS MARKET, BY COUNTRY, 2020-2028 (USD MILLION) 108

TABLE 62 ASIA PACIFIC: ELISPOT AND FLUOROSPOT ANALYZERS MARKET, BY COUNTRY, 2020-2028 (USD MILLION) 108

## 6.4 ANCILLARY PRODUCTS 108

### 6.4.1 REPEATED USAGE OF ANCILLARY PRODUCTS INTEGRAL TO RELIABILITY AND SUCCESS OF ELISPOT AND FLUOROSPOT ASSAYS 108

TABLE 63 ELISPOT AND FLUOROSPOT ANCILLARY PRODUCTS MARKET, BY REGION, 2020-2028 (USD MILLION) 109

TABLE 64 NORTH AMERICA: ELISPOT AND FLUOROSPOT ANCILLARY PRODUCTS MARKET, BY COUNTRY, 2020-2028 (USD MILLION) 109

TABLE 65 EUROPE: ELISPOT AND FLUOROSPOT ANCILLARY PRODUCTS MARKET, BY COUNTRY, 2020-2028 (USD MILLION) 109

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 66	ASIA PACIFIC: ELISPOT AND FLUOROSPOT ANCILLARY PRODUCTS MARKET, BY COUNTRY, 2020-2028 (USD MILLION)	110
7	ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION	111
7.1	INTRODUCTION	112
TABLE 67	ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020-2028 (USD MILLION)	112
7.2	DIAGNOSTIC APPLICATIONS	112
TABLE 68	ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2020-2028 (USD MILLION)	112
TABLE 69	ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2020-2028 (USD MILLION)	113
TABLE 70	NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2020-2028 (USD MILLION)	113
TABLE 71	EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2020-2028 (USD MILLION)	113
TABLE 72	ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2020-2028 (USD MILLION)	114
7.2.1	INFECTIOUS DISEASES	114
7.2.1.1	Rising prevalence of infectious diseases to drive market	114
TABLE 73	ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2020-2028 (USD MILLION)	115
TABLE 74	NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020-2028 (USD MILLION)	115
TABLE 75	EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020-2028 (USD MILLION)	115
TABLE 76	ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020-2028 (USD MILLION)	116
7.2.2	TRANSPLANTS	116
7.2.2.1	Growing incidence of infections caused during transplant procedures to drive demand	116
FIGURE 33	PATIENTS ON WAITING LIST FOR ORGAN TRANSPLANTS, 2023	117
FIGURE 34	NUMBER OF TRANSPLANTS PERFORMED IN 2023	117
TABLE 77	ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR TRANSPLANTS, BY REGION, 2020-2028 (USD MILLION)	118
TABLE 78	NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR TRANSPLANTS, BY COUNTRY, 2020-2028 (USD MILLION)	118
TABLE 79	EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR TRANSPLANTS, BY COUNTRY, 2020-2028 (USD MILLION)	118
TABLE 80	ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR TRANSPLANTS, BY COUNTRY, 2020-2028 (USD MILLION)	119
7.3	RESEARCH APPLICATIONS	119
TABLE 81	ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2028 (USD MILLION)	119
TABLE 82	ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2020-2028 (USD MILLION)	120
TABLE 83	NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020-2028 (USD MILLION)	120
TABLE 84	EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020-2028 (USD MILLION)	120
TABLE 85	ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020-2028 (USD MILLION)	121
7.3.1	VACCINE DEVELOPMENT	121
7.3.1.1	Largest and fastest-growing segment of market	121
TABLE 86	ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR VACCINE DEVELOPMENT, BY REGION, 2020-2028 (USD MILLION)	122
TABLE 87	NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR VACCINE DEVELOPMENT, BY COUNTRY, 2020-2028 (USD MILLION)	122
TABLE 88	EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR VACCINE DEVELOPMENT, BY COUNTRY, 2020-2028 (USD	



MILLION)122

TABLE 891ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR VACCINE DEVELOPMENT, BY COUNTRY, 2020-2028 (USD MILLION)123

7.3.21CLINICAL TRIALS123

7.3.2.11Growing number of clinical trials to drive demand123

FIGURE 351NUMBER OF CLINICAL TRIALS, BY REGION, 2010-2021123

FIGURE 361NUMBER OF REGISTERED CLINICAL STUDIES, 2023124

TABLE 901ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR CLINICAL TRIALS, BY REGION, 2020-2028 (USD MILLION)124

TABLE 911NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR CLINICAL TRIALS, BY COUNTRY, 2020-2028 (USD MILLION)124

TABLE 921EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR CLINICAL TRIALS, BY COUNTRY, 2020-2028 (USD MILLION)125

TABLE 931ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR CLINICAL TRIALS, BY COUNTRY, 2020-2028 (USD MILLION)125

7.3.31CANCER RESEARCH125

7.3.3.11Rising prevalence of cancer to support market growth125

TABLE 941ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR CANCER RESEARCH, BY REGION, 2020-2028 (USD MILLION)126

TABLE 951NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR CANCER RESEARCH, BY COUNTRY, 2020-2028 (USD MILLION)127

TABLE 961EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR CANCER RESEARCH, BY COUNTRY, 2020-2028 (USD MILLION)127

TABLE 971ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR CANCER RESEARCH, BY COUNTRY, 2020-2028 (USD MILLION)127

81ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER128

8.11INTRODUCTION129

TABLE 981ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020-2028 (USD MILLION)129

8.21HOSPITAL AND CLINICAL LABORATORIES129

8.2.11IMPROVING HEALTHCARE INFRASTRUCTURE IN DEVELOPING COUNTRIES TO DRIVE MARKET129

TABLE 991ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR HOSPITAL AND CLINICAL LABORATORIES, BY REGION, 2020-2028 (USD MILLION)130

TABLE 1001NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR HOSPITAL AND CLINICAL LABORATORIES, BY COUNTRY, 2020-2028 (USD MILLION)130

TABLE 1011EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR HOSPITAL AND CLINICAL LABORATORIES, BY COUNTRY, 2020-2028 (USD MILLION)131

TABLE 1021ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR HOSPITAL AND CLINICAL LABORATORIES, BY COUNTRY, 2020-2028 (USD MILLION)131

8.31RESEARCH INSTITUTES131

8.3.11FASTEST-GROWING END USER OF ELISPOT AND FLUOROSPOT ASSAYS131

TABLE 1031GRANTS, BY CANCER TYPE, 2023132

TABLE 1041ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR RESEARCH INSTITUTES, BY REGION, 2020-2028 (USD MILLION)133

TABLE 1051NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2020-2028 (USD MILLION)133

TABLE 1061EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2020-2028 (USD MILLION)133

TABLE 1071ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2020-2028 (USD MILLION)134

8.41BIOPHARMACEUTICAL COMPANIES AND CONTRACT RESEARCH ORGANIZATIONS134

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

#### 8.4.1 GROWTH IN BIOTECHNOLOGY INDUSTRY TO PROPEL GROWTH 134

TABLE 108 ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR BIOPHARMACEUTICAL COMPANIES AND CROS, BY REGION, 2020-2028 (USD MILLION) 135

TABLE 109 NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR BIOPHARMACEUTICAL COMPANIES AND CROS, BY COUNTRY, 2020-2028 (USD MILLION) 135

TABLE 110 EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR BIOPHARMACEUTICAL COMPANIES AND CROS, BY COUNTRY, 2020-2028 (USD MILLION) 135

TABLE 111 ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR BIOPHARMACEUTICAL COMPANIES AND CROS, BY COUNTRY, 2020-2028 (USD MILLION) 136

9 ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY REGION 137

#### 9.1 INTRODUCTION 138

TABLE 112 ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY REGION, 2020-2028 (USD MILLION) 138

#### 9.2 NORTH AMERICA 138

FIGURE 37 NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET SNAPSHOT 139

TABLE 113 NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY COUNTRY, 2020-2028 (USD MILLION) 139

TABLE 114 NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020-2028 (USD MILLION) 140

TABLE 115 NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020-2028 (USD MILLION) 140

TABLE 116 NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020-2028 (USD MILLION) 140

#### 9.2.1 NORTH AMERICA: RECESSION IMPACT 141

#### 9.2.2 US 141

#### 9.2.2.1 Rising prevalence of chronic diseases to drive market 141

TABLE 117 US: KEY MACROINDICATORS 142

TABLE 118 US: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020-2028 (USD MILLION) 142

TABLE 119 US: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020-2028 (USD MILLION) 142

TABLE 120 US: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020-2028 (USD MILLION) 143

#### 9.2.3 CANADA 143

#### 9.2.3.1 Rising healthcare expenditure to drive adoption of ELISpot and FluoroSpot assays 143

TABLE 121 CANADA: KEY MACROINDICATORS 144

TABLE 122 CANADA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020-2028 (USD MILLION) 144

TABLE 123 CANADA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020-2028 (USD MILLION) 145

TABLE 124 CANADA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020-2028 (USD MILLION) 145

#### 9.3 EUROPE 145

TABLE 125 EUROPE: HEALTHCARE EXPENDITURE, BY COUNTRY 146

#### 9.3.1 EUROPE: RECESSION IMPACT 146

TABLE 126 EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY COUNTRY, 2020-2028 (USD MILLION) 147

TABLE 127 EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020-2028 (USD MILLION) 147

TABLE 128 EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020-2028 (USD MILLION) 147

TABLE 129 EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020-2028 (USD MILLION) 148

#### 9.3.2 GERMANY 148

#### 9.3.2.1 Fastest-growing country in European ELISpot and FluoroSpot assays market 148

TABLE 130 GERMANY: KEY MACROINDICATORS 149

TABLE 131 GERMANY: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020-2028 (USD MILLION) 149

TABLE 132 GERMANY: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020-2028 (USD MILLION) 149

TABLE 133 GERMANY: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020-2028 (USD MILLION) 150

#### 9.3.3 UK 150

#### 9.3.3.1 Rising prevalence of NCDs to drive market 150

TABLE 134 UK: KEY MACROINDICATORS 151

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 135	UK: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020-2028 (USD MILLION)	151
TABLE 136	UK: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020-2028 (USD MILLION)	151
TABLE 137	UK: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020-2028 (USD MILLION)	152
9.3.4	FRANCE	152
9.3.4.1	Need for early disease diagnosis to support market growth	152
TABLE 138	FRANCE: KEY MACROINDICATORS	153
TABLE 139	FRANCE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020-2028 (USD MILLION)	153
TABLE 140	FRANCE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020-2028 (USD MILLION)	153
TABLE 141	FRANCE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020-2028 (USD MILLION)	154
9.3.5	ITALY	154
9.3.5.1	Increasing incidence of cancer to propel market	154
TABLE 142	ITALY: KEY MACROINDICATORS	155
TABLE 143	ITALY: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020-2028 (USD MILLION)	155
TABLE 144	ITALY: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020-2028 (USD MILLION)	155
TABLE 145	ITALY: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020-2028 (USD MILLION)	156
9.3.6	SPAIN	156
9.3.6.1	High incidence of chronic diseases to drive market	156
TABLE 146	SPAIN: KEY MACROINDICATORS	157
TABLE 147	SPAIN: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020-2028 (USD MILLION)	157
TABLE 148	SPAIN: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020-2028 (USD MILLION)	157
TABLE 149	SPAIN: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020-2028 (USD MILLION)	158
9.3.7	REST OF EUROPE	158
TABLE 150	REST OF EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020-2028 (USD MILLION)	159
TABLE 151	REST OF EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020-2028 (USD MILLION)	159
TABLE 152	REST OF EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020-2028 (USD MILLION)	160
9.4	ASIA PACIFIC	160
9.4.1	ASIA PACIFIC: RECESSION IMPACT	160
FIGURE 38	ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET SNAPSHOT	161
TABLE 153	ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY COUNTRY, 2020-2028 (USD MILLION)	161
TABLE 154	ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020-2028 (USD MILLION)	162
TABLE 155	ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020-2028 (USD MILLION)	162
TABLE 156	ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020-2028 (USD MILLION)	162
9.4.2	CHINA	163
9.4.2.1	Rising focus on vaccine development and cancer research to drive market	163
TABLE 157	CHINA: KEY MACROINDICATORS	164
TABLE 158	CHINA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020-2028 (USD MILLION)	164
TABLE 159	CHINA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020-2028 (USD MILLION)	164
TABLE 160	CHINA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020-2028 (USD MILLION)	165
9.4.3	JAPAN	165
9.4.3.1	Increased focus on vaccine research to support market growth	165
TABLE 161	JAPAN: KEY MACROINDICATORS	166
TABLE 162	JAPAN: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020-2028 (USD MILLION)	166
TABLE 163	JAPAN: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020-2028 (USD MILLION)	166
TABLE 164	JAPAN: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020-2028 (USD MILLION)	167
9.4.4	INDIA	167
9.4.4.1	Increasing focus on cancer research and therapy to drive market	167
TABLE 165	INDIA: KEY MACROINDICATORS	168

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

TABLE 166	INDIA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020-2028 (USD MILLION)	168
TABLE 167	INDIA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020-2028 (USD MILLION)	168
TABLE 168	INDIA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020-2028 (USD MILLION)	169
9.4.5	REST OF ASIA PACIFIC	169
TABLE 169	REST OF ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020-2028 (USD MILLION)	170
TABLE 170	REST OF ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020-2028 (USD MILLION)	170
TABLE 171	REST OF ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020-2028 (USD MILLION)	170
9.5	REST OF THE WORLD	171
TABLE 172	REST OF THE WORLD: POPULATION AGED 65 AND ABOVE, 2022	171
9.5.1	REST OF THE WORLD: RECESSION IMPACT	172
TABLE 173	REST OF THE WORLD: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020-2028 (USD MILLION)	172
TABLE 174	REST OF THE WORLD: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020-2028 (USD MILLION)	172
TABLE 175	REST OF THE WORLD: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020-2028 (USD MILLION)	173
10	COMPETITIVE LANDSCAPE	174
10.1	OVERVIEW	174
10.2	STRATEGIES ADOPTED BY KEY PLAYERS	174
TABLE 176	OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN ELISPOT AND FLUOROSPOT ASSAYS MARKET	174
10.3	MARKET SHARE ANALYSIS	175
TABLE 177	ELISPOT AND FLUOROSPOT ASSAYS MARKET: DEGREE OF COMPETITION	175
10.4	REVENUE SHARE ANALYSIS	176
FIGURE 39	REVENUE ANALYSIS OF KEY PUBLIC PLAYERS IN ELISPOT AND FLUOROSPOT ASSAYS MARKET	176
FIGURE 40	ELISPOT AND FLUOROSPOT ASSAYS: MARKET RANKING ANALYSIS, 2022	176
10.5	COMPANY EVALUATION MATRIX	178
10.5.1	STARS	178
10.5.2	EMERGING LEADERS	178
10.5.3	PERVASIVE PLAYERS	178
10.5.4	PARTICIPANTS	178
FIGURE 41	ELISPOT AND FLUOROSPOT ASSAYS MARKET: COMPANY EVALUATION MATRIX, 2022	179
10.6	SME/STARTUP EVALUATION MATRIX	180
10.6.1	PROGRESSIVE COMPANIES	180
10.6.2	RESPONSIVE COMPANIES	180
10.6.3	DYNAMIC COMPANIES	180
10.6.4	STARTING BLOCKS	180
FIGURE 42	ELISPOT AND FLUOROSPOT ASSAYS MARKET: SME/STARTUP EVALUATION MATRIX, 2022	181
10.7	COMPETITIVE BENCHMARKING	182
TABLE 178	ELISPOT AND FLUOROSPOT ASSAYS MARKET: DETAILED LIST OF KEY STARTUPS/SMES	182
10.8	COMPANY FOOTPRINT	182
TABLE 179	COMPANY FOOTPRINT	182
TABLE 180	PRODUCT FOOTPRINT	183
TABLE 181	REGIONAL FOOTPRINT	184
10.9	COMPETITIVE SCENARIO	186
10.9.1	PRODUCT LAUNCHES	186
TABLE 182	KEY PRODUCT LAUNCHES, JANUARY 2020-OCTOBER 2023	186
10.9.2	DEALS	186
TABLE 183	KEY DEALS, JANUARY 2020-OCTOBER 2023	186
10.9.3	OTHER DEVELOPMENTS	187
TABLE 184	OTHER KEY DEVELOPMENTS, JANUARY 2020-OCTOBER 2023	187

## 11 COMPANY PROFILES 188

(Business Overview, Products Offered, Recent Developments, MnM View Right to win, Strategic choices made, Weaknesses and competitive threats) \*

### 11.1 KEY PLAYERS 188

#### 11.1.1 OXFORD IMMUNOTEC USA, INC. (SUBSIDIARY OF REVVITY, INC.) 188

TABLE 185 OXFORD IMMUNOTEC USA, INC. (SUBSIDIARY OF REVVITY, INC.): BUSINESS OVERVIEW 188

FIGURE 43 REVVITY, INC.: COMPANY SNAPSHOT (2023) 189

#### 11.1.2 BECTON, DICKINSON AND COMPANY 192

TABLE 186 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW 192

FIGURE 44 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022) 193

#### 11.1.3 BIO-TECHNE 196

TABLE 187 BIO-TECHNE: BUSINESS OVERVIEW 196

FIGURE 45 BIO-TECHNE: COMPANY SNAPSHOT (2023) 197

#### 11.1.4 CELLULAR TECHNOLOGY LIMITED 200

TABLE 188 CELLULAR TECHNOLOGY LIMITED: BUSINESS OVERVIEW 200

#### 11.1.5 MABTECH 203

TABLE 189 MABTECH: BUSINESS OVERVIEW 203

#### 11.1.6 ABCAM PLC 205

TABLE 190 ABCAM PLC: BUSINESS OVERVIEW 205

FIGURE 46 ABCAM PLC: COMPANY SNAPSHOT (2022) 206

#### 11.1.7 MERCK KGAA 209

TABLE 191 MERCK KGAA: BUSINESS OVERVIEW 209

FIGURE 47 MERCK KGAA: COMPANY SNAPSHOT (2022) 210

#### 11.1.8 AUTOIMMUN DIAGNOSTIKA GMBH 212

TABLE 192 AUTOIMMUN DIAGNOSTIKA GMBH: BUSINESS OVERVIEW 212

#### 11.1.9 U-CYTECH 214

TABLE 193 U-CYTECH: BUSINESS OVERVIEW 214

#### 11.1.10 MIKROGEN DIAGNOSTIK 216

TABLE 194 MIKROGEN DIAGNOSTIK: BUSINESS OVERVIEW 216

#### 11.1.11 MEDIX BIOCHEMICA 217

TABLE 195 MEDIX BIOCHEMICA: BUSINESS OVERVIEW 217

#### 11.1.12 ABNOVA CORPORATION 219

TABLE 196 ABNOVA CORPORATION: BUSINESS OVERVIEW 219

#### 11.1.13 ANOGEN-YES BIOTECH LABORATORIES LTD. 220

TABLE 197 ANOGEN-YES BIOTECH LABORATORIES LTD.: BUSINESS OVERVIEW 220

#### 11.1.14 BIORBYT LTD. 221

TABLE 198 BIORBYT LTD.: BUSINESS OVERVIEW 221

#### 11.1.15 BIOSYS SCIENTIFIC DEVICES GMBH 223

TABLE 199 BIOSYS SCIENTIFIC DEVICES GMBH: BUSINESS OVERVIEW 223

### 11.2 OTHER PLAYERS 224

#### 11.2.1 JACKSON IMMUNORESEARCH INC. 224

TABLE 200 JACKSON IMMUNORESEARCH INC.: BUSINESS OVERVIEW 224

#### 11.2.2 IST SCIENTIFIC 225

TABLE 201 IST SCIENTIFIC: BUSINESS OVERVIEW 225

#### 11.2.3 SERVA ELECTROPHORESIS GMBH 226

TABLE 202 SERVA ELECTROPHORESIS GMBH: BUSINESS OVERVIEW 226

#### 11.2.4 ACROBIOSYSTEMS 227

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 203 □ACROBIOSYSTEMS: BUSINESS OVERVIEW□227

11.2.5 □NATIONAL ANALYTICAL CORPORATION□228

TABLE 204 □NATIONAL ANALYTICAL CORPORATION: BUSINESS OVERVIEW□228

11.2.6 □STEMCELL TECHNOLOGIES□229

TABLE 205 □STEMCELL TECHNOLOGIES: BUSINESS OVERVIEW□229

11.2.7 □ZENBIO, INC.□230

TABLE 206 □ZENBIO, INC.: BUSINESS OVERVIEW□230

11.2.8 □BOC SCIENCES□231

TABLE 207 □BOC SCIENCES: BUSINESS OVERVIEW□231

11.2.9 □TOKYO CHEMICAL INDUSTRY CO., LTD.□232

TABLE 208 □TOKYO CHEMICAL INDUSTRY CO., LTD.: BUSINESS OVERVIEW□232

11.2.10 □MP BIOMEDICALS□233

TABLE 209 □MP BIOMEDICALS: BUSINESS OVERVIEW□233

\*Details on Business Overview, Products Offered, Recent Developments, MnM View, Right to win, Strategic choices made, Weaknesses and competitive threats might not be captured in case of unlisted companies.

12 □APPENDIX□234

12.1 □INSIGHTS FROM INDUSTRY EXPERTS□234

12.2 □DISCUSSION GUIDE□235

12.3 □KNOWLEDGESTORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL□239

12.4 □CUSTOMIZATION OPTIONS□241

12.5 □RELATED REPORTS□241

12.6 □AUTHOR DETAILS□242

**ELISpot and FluoroSpot Assay Market by Product (Assay kit (Technique, Utility, Analyte (T Cell and B Cell assay)), Analyzer), Application (Transplants, Infectious Diseases, Vaccine Development, Cancer Research), End User - Global Forecast to 2028**

Market Report | 2023-11-20 | 234 pages | MarketsandMarkets

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	2025-05-19
		Signature	<div></div>